| Name | Tiragolumab |
|---|
| Description | Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab, may be effective against multiple solid malignancies-most notably non-small cell lung cancer[1][2]. |
|---|---|
| Related Catalog | |
| References |
[2]. Tiragolumab Impresses in Multiple Trials. Cancer Discov. 2020 Aug;10(8):1086-1087. |
| No Any Chemical & Physical Properties |